Melvin Belafsky
Neurology · Burbank, CANPI 1831114271
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 86 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 28 manufacturers, the largest accounting for just 14.2% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2022 at $887 and has fallen 97.4% since, to $23 in 2023.
Across 86 payments — averaging $30.53 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Biogen$372
- Neurocrine Biosciences, Inc.$338
- Teva Pharmaceuticals USA, Inc.$252
- MDD US Operations, LLC$244
- SK Life Science, Inc.$209
- Amgen$194
- plus $1K from 22 others
What the payments were for
- Food & beverage$2,624100%
- Education$10%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Biogen | 8 | $372 |
| Neurocrine Biosciences, Inc. | 6 | $338 |
| Teva Pharmaceuticals USA, Inc. | 7 | $252 |
| MDD US Operations, LLC | 13 | $244 |
| SK Life Science, Inc. | 5 | $209 |
| Amgen | 4 | $194 |
| UCB, Inc. | 6 | $180 |
| AbbVie | 6 | $137 |
| E.r. Squibb & Sons, L.L.C. | 2 | $117 |
| Mallinckrodt Hospital Products Inc. | 3 | $71 |
| Sanofi | 3 | $57 |
| Johnson & Johnson | 2 | $49 |
| Grifols USA, LLC | 2 | $47 |
| Livanova USA, Inc. | 2 | $42 |
| Akcea Therapeutics, Inc. | 2 | $41 |
| Mallinckrodt Enterprises LLC | 1 | $33 |
| Travere Therapeutics, Inc. | 2 | $33 |
| Biohaven Pharmaceuticals, Inc. | 2 | $30 |
| Acadia Pharmaceuticals Inc | 1 | $24 |
| Novartis | 1 | $23 |
| Sanofi-aventis U.S. LLC | 1 | $22 |
| Shire North American Group Inc | 1 | $21 |
| Avanir Pharmaceuticals, Inc. | 1 | $20 |
| Jazz Pharmaceuticals Inc. | 1 | $16 |
| AstraZeneca | 1 | $15 |
| Boston Scientific | 1 | $14 |
| Bristol Myers Squibb | 1 | $12 |
| Eisai Inc. | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$2,625 in reported general payments places this provider in the 60th percentile of 1,996 neurology providers in California.
Other neurology in Burbank
- Andrew BlumenfeldCarlsbad$4.9M
- Khashayar DashtipourLoma Linda$3.3M
- Regina BerkovichWest Hollywood$3M
- Daniel BandariNewport Beach$2.6M
- Perry ShiehLos Angeles$2.4M
- Sandeep ThakkarIrvine$2M
- David LiebeskindLos Angeles$1.9M
- Jack SchimCarlsbad$1.7M
- Parshaw DorrizMission Viejo$1.5M
- Benjamin FrishbergCarlsbad$1.2M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.